An Introduction and Overview into Lipid Nanoparticle Technology

Lipid nanoparticles (LNPs) have become the gold standard in non-viral gene delivery technologies, exemplified by the approval of the LNP messenger RNA (mRNA) vaccines against SARS-CoV-2. Since then, there has been substantial growth and interest in the field, with many more RNA-based LNP drugs entering the clinical pipeline for numerous indications, including protein replacement therapies for cystic fibrosis or heart failure; immunotherapies for solid tumours; and vaccines for other viruses such as influenza and zika virus. This webinar will discuss first the historical development of LNPs and the key technological developments that have enabled their success today, followed by an in-depth discussion on the critical components that dictate LNP function. This will be followed by a discussion on the current state-of-the-art in the field, and finally the limitations that will need to be addressed as more LNP-based therapeutics enter the market.

Learning Objectives

• Understand the technological advances and key discoveries that have led to the development of LNPs.
• Explain how the LNP components inform the final nanoparticle physiochemical properties and the ways in which LNPs can be optimized.
• Describe the challenges currently faced in the field and the proposed solutions to help overcome these limitations.

Labroots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.